JO
CRVS icon

John Overdeck’s Corvus Pharmaceuticals CRVS Stock Holding History

John Overdeck’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.7M Buy
785,208
+245,339
+45% +$3.4M 0.01% 1400
2026
Q1 		$7.9M Buy
539,869
+396,271
+276% +$6.32M 0.01% 1596
2025
Q4 		$1.11M Sell
143,598
-59,762
-29% -$471K ﹤0.01% 2845
2025
Q3 		$1.5M Sell
203,360
-20,553
-9% -$105K ﹤0.01% 2321
2025
Q2 		$896K Sell
223,913
-84,437
-27% -$307K ﹤0.01% 2310
2025
Q1 		$981K Buy
308,350
+278,046
+918% +$1.31M ﹤0.01% 2189
2024
Q4 		$162K Sell
30,304
-41,248
-58% -$308K ﹤0.01% 2901
2024
Q3 		$378K Buy
71,552
+23,766
+50% +$85.3K ﹤0.01% 2585
2024
Q2 		$87K Sell
47,786
-54,663
-53% -$102K ﹤0.01% 2838
2024
Q1 		$182K Sell
102,449
-78,255
-43% -$163K ﹤0.01% 2734
2023
Q4 		$318K Sell
180,704
-92,303
-34% -$135K ﹤0.01% 2672
2023
Q3 		$399K Buy
273,007
+18,753
+7% +$39.7K ﹤0.01% 2374
2023
Q2 		$582K Buy
254,254
+50,207
+25% +$104K ﹤0.01% 2264
2023
Q1 		$186K Sell
204,047
-77,140
-27% -$60.2K ﹤0.01% 2575
2022
Q4 		$239K Sell
281,187
-148,521
-35% -$131K ﹤0.01% 2334
2022
Q3 		$352K Buy
429,708
+68,674
+19% +$65.5K ﹤0.01% 1911
2022
Q2 		$357K Sell
361,034
-143,121
-28% -$176K ﹤0.01% 1957
2022
Q1 		$827K Sell
504,155
-426,292
-46% -$780K ﹤0.01% 1797
2021
Q4 		$2.24M Buy
930,447
+789,992
+562% +$3.06M ﹤0.01% 1828
2021
Q3 		$680K Sell
140,455
-169,198
-55% -$501K ﹤0.01% 2983
2021
Q2 		$827K Sell
309,653
-39,103
-11% -$108K ﹤0.01% 2642
2021
Q1 		$1.07M Buy
+348,756
New +$1.26M ﹤0.01% 2243
2020
Q3 		– Sell
-50,776
Closed -$138K – 3165
2020
Q2 		$138K Sell
50,776
-48,482
-49% -$143K ﹤0.01% 2741
2020
Q1 		$209K Sell
99,258
-9,341
-9% -$37.9K ﹤0.01% 2624
2019
Q4 		$591K Buy
108,599
+44,551
+70% +$156K ﹤0.01% 2652
2019
Q3 		$193K Buy
64,048
+17,144
+37% +$72K ﹤0.01% 3202
2019
Q2 		$175K Sell
46,904
-16,957
-27% -$66.4K ﹤0.01% 3120
2019
Q1 		$257K Sell
63,861
-4,839
-7% -$20.4K ﹤0.01% 2694
2018
Q4 		$252K Buy
+68,700
New +$468K ﹤0.01% 2576

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
California State Teachers Retirement System (CalSTRS)
California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

John Overdeck's CRVS Position: Q2 2026 in Review

John Overdeck increased its Corvus Pharmaceuticals (CRVS) stake by 45% in Q2 2026, buying an estimated $3.4M and bringing the position to 785,208 shares worth $11.7M. The position accounts for 0.01% of the portfolio, ranked #1400.

John Overdeck first reported a position in CRVS in Q4 2018 and has held it in 29 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • John Overdeck held 785,208 shares of Corvus Pharmaceuticals worth $11.7M as of Q2 2026.
  • John Overdeck bought 245,339 Corvus Pharmaceuticals shares in Q2 2026, an estimated $3.4M.
  • Corvus Pharmaceuticals made up 0.01% of John Overdeck's portfolio in Q2 2026, its #1400 holding.
  • John Overdeck first reported a position in Corvus Pharmaceuticals in Q4 2018 and has held it in 29 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.